Drug Profile
Pegfilgrastim - Amgen/Kyowa Kirin
Alternative Names: Filgrastim SD01; G-Lasta; KRN 125; Neulasta; Neulasta Onpro® Kit; Neulastim; PEG filgrastim; PEG G-CSF; PEG-rmetHuG-CSF; Pegylated filgrastim; R 1471; r-metHuG-CSF-SD-01; SD-01; SD/01Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Kirin-Amgen
- Developer Amgen; Kyowa Kirin
- Class Antineoplastics; Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
- Mechanism of Action Granulocyte colony-stimulating factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Chemotherapy induced febrile neutropenia; Radiation injuries; Stem cell mobilisation
- Phase II Breast cancer; HER2 positive breast cancer
Most Recent Events
- 31 Jul 2023 Kyowa Kirin applied for partial change of approved indication of Pegfilgrastim in Japan (Kyowa Kirin pipeline, August 2023)
- 25 Oct 2022 Kyowa Kirin completes a phase II trial in Stem cell mobilization in Japan (NCT05007652)
- 13 May 2022 Launched for Stem cell mobilisation in Japan (SC), prior to March 2022 (Kyowa Kirin's pipeline, May 2022)